Soloway, 1986 - Google Patents

Treatment of prostatic cancer: Newer forms of androgen deprivation

Soloway, 1986

Document ID
9631873923783660208
Author
Soloway M
Publication year
Publication venue
Postgraduate Medicine

External Links

Snippet

IIIII Adenocarcinoma of the prostate is among the most common malignancies in men over the age of 55 years. Unfortunately, 30% to 50% of adenocarcinomas have already metastasized when diagnosed. Metastases are found most often in the bone; soft tissue (eg …
Continue reading at www.tandfonline.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Similar Documents

Publication Publication Date Title
Dowsett et al. Suppression of postmenopausal ovarian steroidogenesis with the luteinizing hormone-releasing hormone agonist goserelin
Sandow Clinical applications of LHRH and its analogues
Labrie et al. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist
US6300313B1 (en) Means for treating prostate hypertrophy and prostate cancer
Schulze et al. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate
ES2206622T3 (en) USE OF A GONADOTROPINE LIBERATING HORMONE ANALOG.
Doberauer et al. Advanced male breast cancer treatment with the LH‐RH analogue buserelin alone or in combination with the antiandrogen flutamide
Koutsilieris et al. Gonadotropin‐releasing hormone agonistic analogues in the treatment of advanced prostatic carcinoma
Tolis et al. Suppression of testicular steroidogenesis by the GnRH agonistic analogue Buserelin (HOE-766) in patients with prostatic cancer: studies in relation to dose and route of administration
Smith Jr et al. Testicular histology after prolonged treatment with a gonadotropin-releasing hormone analogue
Chodak Luteinizing hormone-releasing hormone (LHRH) agonists for treatment of advanced prostatic carcinoma
Soloway Treatment of prostatic cancer: Newer forms of androgen deprivation
Klijn et al. LHRH-agonist treatment in metastatic prostate carcinoma
Jackson et al. LHRH analogues in the treatment of cancer
Schwartz et al. Two partial remissions induced by an LHRH analogue in two postmenopausal women with metastatic breast cancer
Wenderotha et al. Endocrine studies with a gonadotropin-releasing hormone analogue to achieve withdrawal of testosterone in prostate carcinoma patients
Swerdloff et al. Effect of GnRH superactive analogs (alone and combined with androgen) on testicular function in man and experimental animals
Blom et al. Pharmacokinetics and endocrine effects of the LHR analogue buserelin after subcutaneous implantation of a slow release preparation in prostatic cancer patients
Shaheen et al. Patient compliance in treatment of prostate cancer with luteinizing hormone-releasing hormone (LHRH) agonist
Tominaga et al. Effect of CGS 16949A plus tamoxifen on induced mammary tumours in rats
Gonzalez‐Barcena et al. Persistent blockade of the pituitary‐gonadal axis in patients with prostatic carcinoma during chronic administration of D‐Trp‐6‐LH‐RH
Rosenberg et al. Hormonal therapy for prostate cancer
Vacher Gn-RH agonists in the treatment of prostatic carcinoma
Falkson et al. Intranasal buserelin in the treatment of advanced prostatic cancer: a phase II trial.
Thomas et al. The endocrinology of normal and abnormal female puberty